Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
COPD, Chronic Obstructive Pulmonary Disease
Study of Ambulatory Respiratory Assist Device in Chronic Obstructive Pulmonary Disease Patients
The study is a two-part small scale, open-label, pilot study to evaluate feasibility and proof-of-concept for a respiratory assist medical device.
- Trial name
- NCT03531489
- Testing
- AIR-AD
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Right-Air
Patients With Asthma-COPD Overlap Syndrome (ACOS)
Non-interventional Study of COPD Patients With Asthma Overlap Syndrome in Viet Nam and Taiwan
The purpose of this study to determine the proportion and clinical characteristics of COPD patients with asthma symptoms (ACOS) and describe current practices in diagnosis and management in Viet Nam and Taiwan.
- Trial name
- NCT02878252
- Where
- 5 sites in Taiwan, Vietnam
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Emphysema, COPD
Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema
This trial is for men and women between the ages of 40 and 74 who have a confirmed diagnosis of emphysema. The objective of the trial is to determine the safety and effectiveness of the IBV Valve at redirecting airflow from…
- Trial name
- IBV®Valve (NCT00475007)
- Testing
- IBV® Valve System
- Where
- 34 sites in United States
- Volunteers
- 277 people
- Sponsor
- Olympus Corporation of the Americas
COPD
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
- Trial name
- GOLDEN 6 (NCT02038829)
- Testing
- SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD
Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product as measured by increases in FEV1.
- Trial name
- NCT03480997
- Testing
- Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Pneuma Respiratory, Inc
COPD
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for…
- Trial name
- GOLDEN-3 (NCT02347761)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer
- Where
- 44 sites in United States
- Volunteers
- 653 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week, open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a day or Spiriva® [tiotropium] given as 18 mcg…
- Trial name
- GOLDEN-5 (NCT02276222)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler
- Where
- 118 sites in United States, Czechia and 2 more
- Volunteers
- 1,087 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD, Chronic Obstructive Pulmonary Disease
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for…
- Trial name
- GOLDEN-4 (NCT02347774)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer
- Where
- 45 sites in United States
- Volunteers
- 641 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD
Evaluation of COPD Co-Pilot
The purpose of undertaking this study is to examine the use of COPD Co-PilotTM, a COPD disease management program manufactured and operated by HGE Health Care Solutions, LLC, in COPD patients outside of the geographic base of…
- Trial name
- NCT03018847
- Testing
- COPD Co-Pilot
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- HGE Health Care Solutions, LLC
COPD
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, parallel arm study. The study population will consist of subjects, 35 to 75 years of age, with a diagnosis of moderate to severe COPD per Global Initiative for Chronic…
- Trial name
- GOLDEN-2 (NCT01706536)
- Testing
- EP-101 12.5 mcg, EP-101 25 mcg, EP-101 50 mcg
- Where
- 26 sites in United States
- Volunteers
- 275 people
- Sponsor
- Sunovion Respiratory Development Inc.
Asthma, Chronic Obstructive Pulmonary Disease COPD
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
This is a randomized, single-blind, placebo-controlled, sequential-group study to assess the safety and tolerability as well as how the drug (AZD7594) affects the body (pharmacodynamics [PD]) and how the body affects the drug…
- Trial name
- NCT02645253
- Testing
- AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Asthma
A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants
AZD7594 is a non steroidal, potent and selective modulator of the glucocorticoid receptor (GR) under development for once daily inhaled treatment of chronic obstructive pulmonary disease (COPD) and asthma.
- Trial name
- NCT02967159
- Testing
- Abediterol, AZD7594, AZD7594/abediterol
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers
This study is an open label, randomized, three-way crossover study to assess the effect of particle size on the PK and safety of single inhaled doses of AZD7594 in healthy subjects (males aged 18 to 55 years [inclusive]).
- Trial name
- NCT02928354
- Testing
- Treatment A - AZD7594, Treatment B - AZD7594, Treatment C - AZD7594
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COPD
Pilot Study Evaluating Feasibility and Benefits of Telemonitored NIV Treatment on COPD Patients
Pilot study evaluating feasibility and benefits of telemonitored NIV (noninvasive ventilation) treatment on COPD (chronic obstructive pulmonary disease) patients.
- Trial name
- eCOPD (NCT02258191)
- Testing
- telemonitoring
- Where
- France
- Volunteers
- 20 people
- Sponsor
- ResMed
COPD
Aerosure and Six Minute Walk Distance in Severe COPD
To investigate whether high frequency airflow oscillation (HFAO), delivered using Aerosure, increases six minute walk distance (6MWD) and reduces exertional breathlessness in patients with severe chronic obstructive pulmonary…
- Trial name
- ACCORD (NCT02007590)
- Testing
- Aerosure 25 Hz
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Actegy Ltd.
COPD
Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
The study is an observational multicenter descriptive study. It is planned to enroll approximately 1250 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or…
- Trial name
- CLOUD (NCT02346292)
- Where
- 30 sites in Russia
- Volunteers
- 1,250 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive (COPD)
Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare in COPD patients naïve to DPIs, the perception of the Breezhaler® and Ellipta® devices' feedback mechanisms evaluated using a preference questionnaire.
- Trial name
- Advantage (NCT02551224)
- Testing
- Patient preference questionnaire
- Where
- 10 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Obstructive Airways Diseases in Emergency Department (OADED) Study
This is an observational study which aims to evaluate the possibility of using data from a capnography device to assess obstructive airway severity in both Chronic Obstructive Pulmonary Disease (COPD) and Asthma patients.
- Trial name
- NCT02805127
- Volunteers
- 12 people
- Sponsor
- Oridion
COPD Patients
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- RISE (NCT02157935)
- Testing
- Symbicort, Formoterol turbohaler
- Where
- 371 sites in United States, Argentina and 9 more
- Volunteers
- 2,026 people
- Sponsor
- AstraZeneca